Innoviva, Inc. (INVA)

Market Cap	943.98M
Revenue (ttm)	310.46M
Net Income (ttm)	179.72M
Shares Out	63.23M
EPS (ttm)	2.20
PE Ratio	6.79
Forward PE	18.07
Dividend	n/a
Ex-Dividend Date	n/a

Volume	776,389
Open	14.98
Previous Close	14.95
Day's Range	14.83 - 15.16
52-Week Range	11.37 - 16.86
Beta	0.58
Analysts	Strong Buy
Price Target	22.50 (+50.7%)
Earnings Date	May 7, 2024

About INVA

Innoviva, Inc. engages in the development and commercialization of pharmaceutical products in the United States and internationally. The company's products include RELVAR/BREO ELLIPTA, a once-daily combination medicine consisting of a LABA, vilanterol (VI), an inhaled corticosteroid (ICS), and fluticasone furoate; ANORO ELLIPTA, a once-daily medicine combining a long-acting muscarinic antagonist (LAMA) and umeclidinium bromide (UMEC) with a LABA, VI; GIAPREZA (angiotensin II), a vasoconstrictor to increase blood pressure in adults with septic o...

• Industry: Biotechnology
• Sector: Healthcare
• IPO Date: Oct 5, 2004
• Employees: 112
• Stock Exchange: NASDAQ
• Ticker Symbol: INVA

Financial Performance

In 2023, Innoviva's revenue was $310.46 million, a decrease of -6.30% compared to the previous year's $331.34 million. Earnings were $179.72 million, a decrease of -15.99%.

Analyst Forecast

According to one analyst, the rating for INVA stock is "Strong Buy" and the 12-month stock price forecast is $22.5.

Price Target

$22.5

(50.70% upside)

Analyst Consensus: Strong Buy